SURABAYA | JATIMSATUNEWS.COM: The United States Department of Defense (Pentagon) has officially removed Chinese biotechnology and pharmaceutical research giant WuXi AppTec from its Chinese military companies blacklist (Section 1260H).
The decision, published in the U.S. government’s official journal, the Federal Register, earlier this week, marks a significant legal victory for WuXi AppTec while bringing much-needed relief to the global pharmaceutical supply chain.
The delisting was authorized directly by the U.S. Deputy Secretary of Defense to comply with an order from the U.S. District Court for the District of Columbia. In its official notice, the Pentagon stated that the removal of WuXi AppTec took effect in early November 2026.
Read also: Adnan Aziz: The Beninese Footballer Reaching Beyond Borders In Pursuit Of His Dream
Sorotan
Washington vs WuXi
Timeline of the Legal Battle
Tensions between Washington and WuXi AppTec peaked on June 8, 2026, when the Pentagon expanded its Section 1260H blacklist to include 188 Chinese entities accused of having ties to or supporting Beijing’s military modernization.
Alongside WuXi AppTec, the expanded list also targeted other major Chinese tech and automotive giants, including Alibaba, Baidu, and BYD.
Just three days after the designation, on June 11, 2026, WuXi AppTec’s management filed a lawsuit against the U.S. Department of Defense in federal court.
The company argued that the “Chinese military company” label was arbitrary, erroneous, and lacked factual basis. WuXi maintained that it is an independent, publicly traded company strictly engaged in commercial drug research and manufacturing services for over 4,000 global clients, with no involvement in China’s military-civil fusion programs.
The legal challenge bore fruit on August 7, 2026, when Chief U.S. District Judge James Boasberg granted WuXi AppTec’s motion for a preliminary injunction.
In his ruling, the judge noted that the Pentagon’s rationale for adding WuXi to the blacklist was unsupported by the evidence and misconstrued the facts.
The court barred the Pentagon from enforcing any penalties tied to the designation, culminating in the formal delisting this week.
Read also: The Light from Malang to Notodden
Shares Surge on Positive Market Sentiment
News of the U.S. blacklist removal drew an immediate positive reaction from capital market investors. In a regulatory filing to the Hong Kong Stock Exchange on Tuesday (Nov. 10, 2026), WuXi AppTec stated that the delisting frees the company from the adverse regulatory consequences of the U.S. defense designation.
Shortly after the announcement, WuXi AppTec shares listed in Hong Kong jumped more than 6 percent in early trading, hitting an intraday high of HK$209.6 per share.
Although the stock saw some profit-taking ahead of the market close, shares under the ticker 2359 remained firmly in positive territory, closing up between 1.21 percent and 2.5 percent.
Citi market analyst John Yung noted that the delisting provides a strong tailwind not only for WuXi AppTec’s stock, but also for the broader Chinese contract research organization (CXO) subsector.
Investor fears over potential forced contract terminations by international clients have now eased considerably.
Major Impact on the Global Pharmaceutical Industry
The removal of WuXi AppTec from the blacklist carries critical implications for the global healthcare and pharmaceutical ecosystem.
For over two decades, WuXi AppTec has served as a vital Contract Research, Development, and Manufacturing Organization (CRDMO) backbone for thousands of biotech firms and major pharmaceutical companies across the United States and Europe.
The North American market accounts for the lion’s share—more than 60 to 70 percent—of WuXi AppTec’s total revenue. Previously, WuXi’s inclusion on the Section 1260H list sparked alarm among U.S. drugmakers.
Under U.S. defense procurement rules and overlapping legislation such as the BIOSECURE Act, blacklisted companies are barred from receiving federally funded contracts, creating severe reputational and compliance pressures for private partners working with them.
Had those restrictions been fully enforced, industry experts warned that the global pharmaceutical sector would have faced severe supply chain disruptions.
Relocating clinical trials and active pharmaceutical ingredient (API) manufacturing away from WuXi to other countries would take years and cost billions of dollars, ultimately threatening the availability of life-saving medicines for patients.
Business Fundamentals Remain Resilient Amid Pressure
Notably, despite facing geopolitical headwinds between Washington and Beijing throughout 2026, WuXi AppTec’s underlying business fundamentals have remained strong.
In its latest financial report, the company posted a 39 percent year-on-year surge in revenue to 45.54 billion yuan (approximately US$6.8 billion) for the first nine months of 2026. The company also raised its full-year revenue guidance to roughly 61 billion yuan.
Nevertheless, legal observers and industry analysts caution that the victory remains procedurally provisional. In its Federal Register filing, the Pentagon noted that the delisting was executed “without prejudice”.
This means the U.S. government retains the legal leeway to re-add WuXi AppTec to the blacklist in the future if the Pentagon can present stronger evidence or a new legal basis.
For now, their leadership emphasized that its primary focus remains serving its global partners.
“This decision relieves the company from further adverse impacts resulting from the Section 1260H designation. We remain fully committed to serving our customers in bringing life-saving and life-improving therapies and medicines to patients worldwide,” the company stated in its official release.***
Author: YAN
Komentar Pembaca
Belum ada komentar pada artikel ini. Jadilah yang pertama.
Minimal 10 karakter, maksimal 1000. Maksimal satu tautan. Semua komentar ditinjau redaksi sebelum tampil.